Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05914636 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Intestinal Microbiota Implication in Ruptured Intracranial Aneurysm

Study acronym: AneBiote
StatusUnknown
PhaseNot specified
Started2024-08-31
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 17, 2024 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Not Yet Recruiting → Unknown
2024-04-16
Study Status v3
Trial statusNot Yet Recruiting→Unknown
Primary completion date2025-12-31→2026-08-31
Completion date2025-12-31→2026-08-31
Start date2024-01-31→2024-08-31
2023-09-21
Study Status v2
Primary completion date2025-07-31→2025-12-31
Completion date2025-07-31→2025-12-31
Start date2023-07-31→2024-01-31
2023-06-22
Study Status, Arms and Interventions, Outcome Measures, Eligibility v1
Eligibility criteriarevised
[...] asing the incidence of aneurysm ( kidney autosomic dominant polykystosispolycystosis, Type 1 neurofibromatosis, Rendu-Osler, MArfan Participation to a study with the objective of microbiota modification
Primary endpoints1 entry, revised
TaxinomicTaxonomic faecal microbiota description
2023-06-13
Original filing
The physiopathology of intracranial aneurysm from initiation to ruptured is incompletely understood but included inflammation. The microbiota is known to interact with brain and can promote inflammation. The objective of this study is to describe microbiota with taxonomic and metabolomic analysis. A comparison between ruptured and unruptured intracranial aneurysm will be performed. The study hypothesis is that microbiota is different between ruptured and unruptured patient.
Trial Details
NCT Number NCT05914636
Lead Sponsor Hospices Civils de Lyon
Conditions Intracranial Sacciform Aneurysm
Enrollment 50 participants
Start Date 2024-08-31
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-17